Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine for CINV Prevention in Moderately Emetogenic Chemotherapy
NCT06850454Phase 3Recruiting
- Sponsor
- Mahidol University
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced nausea and vomiting (CINV) comparing Olanzapine Arm with Placebo Arm (2 arms). Primary endpoint: Total protection rate of nausea and vomiting at 5 days. Started Jan 2025; status: recruiting.
02
Drugs
olanzapine
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT06850454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06850454.